Ovarian Cancer Stage IV Clinical Trial
Official title:
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. This study plans to use ctDNA dynamic monitoring to detect minimal residual lesions during treatment, to demonstrate the application value of ctDNA dynamic monitoring in predicting the recurrence of ovarian cancer after PDS/IDS surgery.
This study plans to include ovarian cancer patients who have undergone PDS/IDS surgery. By analyzing the surgical tissue samples of ovarian cancer patients, we aim to identify risk factors related to the prognosis and recurrence of ovarian cancer. By monitoring the ctDNA status after PDS surgery, we analyze the role of ctDNA-MRD in predicting postoperative recurrence of ovarian cancer. By monitoring the MRD status at the end of the 3rd cycle of adjuvant chemotherapy and at the end of adjuvant treatment, we analyze the predictive role of serial cDNA-MRD for the efficacy of adjuvant treatment, providing a basis for determining the number of cycles of adjuvant treatment after PDS. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT00945191 -
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03579394 -
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04701645 -
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT03126812 -
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03922776 -
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
|
N/A | |
| Completed |
NCT03085238 -
Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04938583 -
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06017557 -
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)
|
N/A | |
| Suspended |
NCT05479045 -
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
|
Phase 2 | |
| Completed |
NCT05005650 -
Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
|
||
| Recruiting |
NCT03899610 -
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
|
Phase 2 | |
| Recruiting |
NCT04789694 -
Prehabilitation in Gynaecological Cancer Patients
|
Phase 3 | |
| Not yet recruiting |
NCT05187208 -
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
|
Phase 4 | |
| Recruiting |
NCT06272240 -
Tumor Microenvironment in Ovarian Cancer
|
||
| Not yet recruiting |
NCT06268665 -
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
|
Phase 2 | |
| Active, not recruiting |
NCT03275506 -
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
|
Phase 2 | |
| Recruiting |
NCT06290193 -
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
|
Phase 2 | |
| Completed |
NCT02258165 -
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
|